| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock","as_of":"2026-04-20T13:10:00.946643+00:00","canonical_url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock","article_chars":3026,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_3e7f202b6206e12e","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-20T13:18:15.926431+00:00","extraction_method":"trafilatura","fetched_description":"Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.","fetched_title":"Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? | Nasdaq","final_url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock","source_event_id":"evt_597745d72808","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"5b822c89f509d9ae","kind":"new_listings","published_at":"2026-04-20T11:59:00+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"Cartesian Therapeutics, Inc.","relevance":"high","symbol":"RNAC","type":"company"},{"asset_class":"equity","name":"Precision BioSciences","relevance":"medium","symbol":"DTIL","type":"company"},{"asset_class":"other","name":"Nasdaq, Inc.","relevance":"low","symbol":"","type":"publisher"}],"event_type":"price_action","information_gaps":["No specific date for the \u201clast trading session\u201d is provided.","The article does not quantify the \u201chigher-than-average\u201d volume beyond that qualitative description.","No details are given on the magnitude of the company\u2019s pipeline goals/updates for 2026 beyond stating they were provided.","The article does not specify the exact date of the upcoming report.","The \u201cempirical research\u201d correlation is referenced but not sourced or quantified in the provided text."],"key_facts":["RNAC shares closed the last trading session up 10.3% at $7.04.","The price jump occurred on higher-than-average trading volume (more shares changing hands than average).","RNAC is reported to have lost 2.9% over the past four weeks.","The company reported robust financial results for the fourth quarter and full-year 2025 and provided pipeline goals/updates for 2026 (as described in the article).","Upcoming report expectations: consensus EPS loss of $0.84 per share, year-over-year change of -23.5%.","Upcoming report expectations: revenues expected at $0.43 million, down 61.4% year over year.","Earnings estimate revisions: consensus EPS estimate revised 2.5% lower over the last 30 days to the current level.","The article states a negative trend in earnings estimate revisions usually does not translate into price appreciation.","RNAC Zacks Rank is #3 (Hold).","DTIL closed up 4.7% at $7.88 and returned 12.1% in the past month (industry comparison in the article).","DTIL upcoming report: consensus EPS estimate changed +40.2% over the past month to -$0.27; described as +87.8% from what the company reported a year ago.","DTIL Zacks Rank is #3 (Hold)."],"numeric_claims":[{"label":"RNAC last session move","value":"10.3% higher"},{"label":"RNAC closing price","value":"$7.04"},{"label":"RNAC past four weeks performance","value":"-2.9%"},{"label":"EPS (upcoming)","value":"-$0.84 per share"},{"label":"EPS YoY change","value":"-23.5%"},{"label":"Revenue (upcoming)","value":"$0.43 million"},{"label":"Revenue YoY change","value":"-61.4%"},{"label":"EPS estimate revision (30 days)","value":"-2.5%"},{"label":"RNAC Zacks Rank","value":"#3 (Hold)"},{"label":"DTIL last session move","value":"4.7% higher"},{"label":"DTIL closing price","value":"$7.88"},{"label":"DTIL past month return","value":"12.1%"},{"label":"DTIL EPS estimate (upcoming)","value":"-$0.27"},{"label":"DTIL EPS estimate change (30 days)","value":"+40.2%"},{"label":"DTIL EPS change vs year ago (as described)","value":"+87.8%"},{"label":"DTIL Zacks Rank","value":"#3 (Hold)"}],"primary_claim":"RNAC shares ended the last trading session up 10.3% to $7.04 on higher-than-average trading volume.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Cartesian Therapeutics (RNAC) rose 10.3% to $7.04 on higher-than-average trading volume. The article notes recent earnings estimate revisions have moved lower over the past 30 days, which may limit near-term upside.","topics":["stock price move","trading volume","earnings estimate revisions","earnings outlook","Zacks Rank","biomedical/genetics industry"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.","tickers":["RNAC"],"title":"Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?","url":"https://www.nasdaq.com/articles/cartesian-therapeutics-inc-rnac-soars-103-further-upside-left-stock"}... |